Shawn O’Connor: Sure. Very excited about the two partnerships that we put in place and want to emphasize that our focus here is in terms of demonstrating the value and capabilities of our AI machine learning technology, working with two organizations that will supply the data, in many cases, the knowledge of the target and the candidates are — our services support team will provide the support along with our technology to apply our AI/ML technology to lead generation process there, very hopeful that it produces success with a focus on it being a driver in terms of our software licensing business and our consulting business in this area. Having those case studies and success stories is what will drive that. And as you know, our focus has been in terms of being a tool provider to our clients as opposed to a drug developer.
Now you enter into these relationships. And one of the benefits of them is that it’s very common for some shared success triggers to be involved. And in one case, it is a joint ownership of compounds that may come out of the program. And in the other case, it’s a defined royalty stream associated with them. So while that’s not our primary focus, it is a nice icing-on-the-cake opportunity. Understand that these programs do take some time to come to fruition. So I don’t see any impact from those two opportunities in the near-term future for us, but certainly a nice opportunity in the long run.
Matt Hewitt: That’s great. And obviously, we’ll — hopefully you’ll keep us apprised as those progress. And then maybe one last one, and I’m not sure if you’re going to have this handy, but I’ll throw it out there anyway. You did mention you’re basically moving into a couple of new markets. And I’m just curious, one being outside of therapeutics, it sounded like — are there TAMs associated with those market opportunities? Or is it — were these more very early stage one-off situations if, depending upon how things go, then maybe it becomes a new market for you? Thank you.
Shawn O’Connor: Yes, Matt, the agrochemical partnership with collaboration that we’ve been working there certainly opens up more business opportunity for our support in that industry segment, which has a very small footprint. And today, 5% of our business is done outside of the pharma world in support of the cosmetics industry and other adjacencies. This would go into that bucket and certainly would add some TAM to our opportunity on a go-forward basis. The other one I think you might be referring to is the biologics collaboration. And that certainly is not a brand new market for us. We do participate in that market already, but increasing our functionality footprint and experience in that area gives us more opportunity to take market share in that segment.
Matt Hewitt: Got it. All right. Thank you so much.
Shawn O’Connor: Take care, Matt.
Operator: Our next question comes from the line of Mitra Ramgopal with Sidoti. Please proceed with your question.
Mitra Ramgopal: Yes, good afternoon. Thanks for taking the questions. First, just curious on the churn you’re seeing in small biotech accounts, if that’s continuing now into the third quarter? And is it stabilizing? Or is it even moving on to maybe medium-sized companies?
